TY - JOUR
T1 - Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma
T2 - Analysis According to Gender, Race, Stage, Grade, and Histology
AU - Palumbo, Carlotta
AU - Pecoraro, Angela
AU - Knipper, Sophie
AU - Rosiello, Giuseppe
AU - Luzzago, Stefano
AU - Deuker, Marina
AU - Tian, Zhe
AU - Shariat, Shahrokh F.
AU - Simeone, Claudio
AU - Briganti, Alberto
AU - Saad, Fred
AU - Berruti, Alfredo
AU - Antonelli, Alessandro
AU - Karakiewicz, Pierre I.
N1 - Publisher Copyright:
© 2020 European Association of Urology
PY - 2021/5
Y1 - 2021/5
N2 - Background: Recent data showed that North America has the highest incidence of renal cell carcinoma (RCC) worldwide. Objective: To assess contemporary gender-, race-, and stage-specific incidence; survival rates; and trends of RCC patients in the USA. Design, setting, and participants: Within the Surveillance, Epidemiology, and End Results database (2001–2016), all patients aged ≥18 yr with histologically confirmed renal parenchymal tumors were included. Outcome measurements and statistical analysis: Age-adjusted incidence rates and 5-yr cancer-specific survival (CSS) rates were estimated. Temporal trends were calculated through Joinpoint regression analyses to describe the average annual percent change (AAPC). Results and limitations: The age-adjusted incidence rate of RCC was 11.3/100 000 person years (AAPC + 2.0%, p < 0.001). Five-year CSS rates increased from 78.4% to 84.5% (AAPC +0.8%, p < 0.001). Male incidence was double that of females (15.5 and 7.7, respectively). CSS marginally favored females (84.5% vs 82.0%), but improved equally in both genders (both AAPC +0.8%). The highest incidence (14.1/100 000 person years, AAPC +2.8%) and lowest survival (80.1%) were recorded in non-Hispanic American Indian/Alaska Native populations. T1aN0M0 had the highest incidence rates (4.6/100 000 person years), the highest increase over time (AAPC +3.6%), and the highest CSS (97.6%) of all stages. Limitations include retrospective nature and lack of information on risk factors. Conclusions: The incidence of RCC increased significantly from 2001 to 2016, and 5-yr CSS after RCC improved. This was mainly due to T1aN0M0 tumors that showed the highest increase in the incidence and highest CSS. Unfavorable outcomes in specific ethnic groups warrant further research. Patient summary: We examined contemporary incidence and cancer-specific survival rates of kidney cancer. Males had double the incidence rates of females, but lower survival. Natives showed the highest incidence rates and the lowest survival rates. Small renal masses showed the highest incidence and survival rates.
AB - Background: Recent data showed that North America has the highest incidence of renal cell carcinoma (RCC) worldwide. Objective: To assess contemporary gender-, race-, and stage-specific incidence; survival rates; and trends of RCC patients in the USA. Design, setting, and participants: Within the Surveillance, Epidemiology, and End Results database (2001–2016), all patients aged ≥18 yr with histologically confirmed renal parenchymal tumors were included. Outcome measurements and statistical analysis: Age-adjusted incidence rates and 5-yr cancer-specific survival (CSS) rates were estimated. Temporal trends were calculated through Joinpoint regression analyses to describe the average annual percent change (AAPC). Results and limitations: The age-adjusted incidence rate of RCC was 11.3/100 000 person years (AAPC + 2.0%, p < 0.001). Five-year CSS rates increased from 78.4% to 84.5% (AAPC +0.8%, p < 0.001). Male incidence was double that of females (15.5 and 7.7, respectively). CSS marginally favored females (84.5% vs 82.0%), but improved equally in both genders (both AAPC +0.8%). The highest incidence (14.1/100 000 person years, AAPC +2.8%) and lowest survival (80.1%) were recorded in non-Hispanic American Indian/Alaska Native populations. T1aN0M0 had the highest incidence rates (4.6/100 000 person years), the highest increase over time (AAPC +3.6%), and the highest CSS (97.6%) of all stages. Limitations include retrospective nature and lack of information on risk factors. Conclusions: The incidence of RCC increased significantly from 2001 to 2016, and 5-yr CSS after RCC improved. This was mainly due to T1aN0M0 tumors that showed the highest increase in the incidence and highest CSS. Unfavorable outcomes in specific ethnic groups warrant further research. Patient summary: We examined contemporary incidence and cancer-specific survival rates of kidney cancer. Males had double the incidence rates of females, but lower survival. Natives showed the highest incidence rates and the lowest survival rates. Small renal masses showed the highest incidence and survival rates.
KW - Epidemiology
KW - Incidence
KW - Kidney cancer
KW - Mortality
KW - Renal cell carcinoma
UR - https://www.scopus.com/pages/publications/85085178149
U2 - 10.1016/j.euf.2020.05.003
DO - 10.1016/j.euf.2020.05.003
M3 - Article
SN - 2405-4569
VL - 7
SP - 644
EP - 652
JO - European Urology Focus
JF - European Urology Focus
IS - 3
ER -